Promotion of Wound Healing in Diabetic Foot Ulceration with the Tennant Biomodulator and Tennant BioTransducer
Researched by Lilia Feria NMD, Anthony Pinazza NMD & Joe TiIchen’s NMD
“Diabetic foot ulceration is major source of morbidity with an estimated prevalence of 9- 25% among the estimated 30.3 million people with diabetes in the United States (1-4). Approximately 5.0 per 1,000 people with diabetes will undergo limb amputation annually (5). As ulceration significantly amplifies risk of amputation, improvements to limb salvage efforts are needed.
Current best practices in the management diabetic foot wounds involve three major elements: regular monitoring, wound cleaning and dressing, and mechanical off-loading (6-7). These strategies focus on mitigation of factors that may inhibit wound healing. Estimated rates of wound healing are 1-2% per day with standard methods (8). While glucose control is standard in management of diabetes, significant evidence has not been found to correlate glucose control and wound healing (9). A large number of treatments undergoing evaluation focus on reducing risk of infection while waiting for wound closure but do not yield enhanced rates of closure. Hyperbaric oxygen therapy has shown some evidence of improving healing rates, but quality of data does not yet support generalized recommendations for this treatment (10). Other approaches to biochemically enhance biological processes at work in the wound have not provided evidence of improved rates of healing. Physical therapies such as microcurrent and pEMF have shown positive but limited evidence in small studies of improving rates of healing (11-12). ”